Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ITCA 650 in Renal Impairment
NCT02320045Phase 1Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Peptides, Device-based Delivery
- Countries
- 2
01
Overview
Phase 1, open-label trial of ITCA 650 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Intarcia Therapeutics. Primary endpoint: 24-h Area under the Curve at steady state at Day 67. Started Nov 2014; status: completed.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02320045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320045.